Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Study identifies new biomarker for early lung cancer diagnosis

High levels of cytoskeleton-associated protein 4 (CKAP4) have been identified in the blood of patients with lung cancer.

8 May 2018

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

New immunotherapy treatments offer a remarkable chance for survival for patients with advanced melanoma and hard-to-treat cancers of the bladder, kidney and lung.

4 May 2018

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.

27 Apr 2018

New drug for migraine in the pipeline

According to a pilot study results released yesterday (17th of April 2018), a new drug may help provide relief to people with migraine that is unsuccessfully treated with the currently available drugs.

18 Apr 2018

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events by 15 percent compared with placebo, in a study presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018

Innovative antibody delivery method could offer effective way to combat Ebola infection

More than 11,000 people died during the Ebola outbreak in West Africa from 2013-16, demonstrating both the deadly nature of the virus and the limitations of the medication used to fight it.

6 Mar 2018

Highly sensitive ELISA method for analysis of CET in plasma samples

This article explores the development, full optimization and validation study of a highly sensitive and selective ELISA for determination of cetuximab (CET) in human plasma samples.

23 Feb 2018

AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies

AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and other neurodegenerative diseases.

20 Feb 2018

Extending dosing intervals makes common multiple sclerosis drug safer to use

A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists NYU Langone Health.

5 Feb 2018

UAMS Myeloma Institute expert compiles new book on Castleman disease

Castleman disease, a rare disorder of the lymph nodes and related tissues, was identified and named more than a half-century ago but, until recently, no one had written a book exclusively about it.

30 Jan 2018

New TSRI study uncovers workings of first potential treatment for Marburg virus

With a mortality rate of up to 88 percent, Marburg virus can rip through a community in days. In 2005, an outbreak of Marburg virus struck a pediatric ward in the country of Angola. With no treatment available, doctors struggled to help as the virus killed 329 of 374 infected patients.

11 Jan 2018

Adrenomedullin could serve as biomarker, therapeutic target in disorders caused by leaky blood vessels

Disorders caused by a leaky vasculature are more common than most people think. Despite ICU treatment, one third of the 27 million patients globally that suffer from sepsis, and up to 20% of the more than 5 million US patients with congestive heart failure die every year from their condition.

5 Jan 2018

Two immunotherapy approaches for multiple myeloma show hope

Researchers from the University of Pennsylvania's Abramson Cancer Center have developed two experimental immunotherapy methods that include one chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma patients who were not responding to other treatments.

11 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Study unveils new immunotherapeutic target against multiple myeloma

Osaka - In recent decades monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both solid tumors and blood cancers.

27 Nov 2017

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

14 Nov 2017

Monoclonal antibody effectively blocks development of graft-versus-host disease, research shows

Newly published research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease (GvHD), a potentially lethal complication of bone marrow stem cell (BMSC) transplantation.

14 Nov 2017

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Novartis today announced full results from the positive Phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) vs. interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

30 Oct 2017

Monoclonal antibody “cocktail” inhibits Zika infection, study reveals

A collaborative study conducted by the Miller School of Medicine, University of Miami has revealed that a monoclonal antibody “cocktail” inhibited zika virus (ZIKV) infection in primates.

5 Oct 2017

Researchers identify role of tumor-infiltrating B-cells in melanoma progression, resistance to therapy

In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells ("TABs") in melanoma progression and resistance to targeted therapy.

20 Sep 2017

Monoclonal Antibody News and Research

Further Reading

Study identifies new biomarker for early lung cancer diagnosis

Ocular oncologists link immunotherapy with potentially vision-robbing side effect

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

New drug for migraine in the pipeline

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Innovative antibody delivery method could offer effective way to combat Ebola infection

Highly sensitive ELISA method for analysis of CET in plasma samples

AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies

Extending dosing intervals makes common multiple sclerosis drug safer to use

UAMS Myeloma Institute expert compiles new book on Castleman disease

New TSRI study uncovers workings of first potential treatment for Marburg virus

Adrenomedullin could serve as biomarker, therapeutic target in disorders caused by leaky blood vessels

Two immunotherapy approaches for multiple myeloma show hope

New first line combination therapy shows promising results in patients with advanced NSCLC

Study unveils new immunotherapeutic target against multiple myeloma

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

Monoclonal antibody effectively blocks development of graft-versus-host disease, research shows

Novartis PARADIGMS study shows safety and efficacy of new treatment in pediatric MS patients

Monoclonal antibody “cocktail” inhibits Zika infection, study reveals

Researchers identify role of tumor-infiltrating B-cells in melanoma progression, resistance to therapy

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®